PGXL Laboratories provides pharmacogenetic testing and interpretive services. It has developed CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers
The Phase 3 trials include two studies in treatment-naive and one study in treatment-experienced chronic genotype-1 HCV patients. Boehringer Ingelheim expects to conduct the two Phase 3 studies
The biodegradable nanoparticles could be topically applied to the skin or injected into the body to treat MRSA skin infections. IBM Research – Almaden Advanced Organic Materials scientist
The research agreement, which was previously signed in March 2003, has been extended for another year. Accordingly, the term of the agreement will end in March 2012. As
Munshi is a co-founder and the former chief business officer of KYTHERA Biopharmaceuticals. Before KYTHERA, Munshi was the general manager of Amgen’s European Nephrology Business, with responsibility for
REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active control agent. The study results showed that
As per the agreement, Genzyme expects to provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the
The new cancer treatment also attracts tumours directly. Tracy Robson and her research team at Queen’s, in collaboration with researchers at Almac Discovery, developed a new drug to
The ALN-VSP Phase I trial is designed to recruit patients with advanced solid tumors with liver involvement who have failed to respond to or have progressed after standard
Daxas (roflumilast) is an orally administered selective phosphodiesterase 4 (PDE4) enzyme inhibitor, which has been shown to inhibit COPD related inflammation with a novel mode of action. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.